Cardiac AI: What Market Numbers Really Measure

The cardiac AI market is a paradox for investors. It’s a category exploding with growth and technological promise, yet the actual revenue is concentrated in the hands of just a few companies. To understand this, you have to look past the headline numbers and dig into how individual companies are actually performing. This analysis shows what those reported market figures truly measure and focuses on the regulatory and reimbursement pathways that are absolutely required to turn an algorithm into a commercially successful product.

The Headline Numbers: Promise Across a Wide Field

Market estimates from Mordor Intelligence show a massive opportunity in cardiac AI monitoring and diagnostics. The category was pegged at $2.05 billion in 2024 and is expected to rocket up at a 28.6 percent compound annual growth rate (CAGR) through 2029 Mordor Intelligence cardiac AI market report. This strong growth covers a huge range of AI applications, from imaging and monitoring to cardiac risk prediction models. With over 100 active companies in the field, it looks like a hotbed of activity. All this action, spread across so many technologies and players, is what builds up that impressive overall market valuation. It suggests that AI is poised to make a real dent in cardiovascular disease, which is still a leading killer worldwide. But if you look at what individual companies are bringing in, you get a much different picture than the aggregate market size suggests.

Revenue Concentration: A Deeper Look at Commercial Scale

While the market estimates suggest widespread activity, the revenue is anything but. The money trail tells a much more focused story. Take HeartFlow, a big name in cardiac imaging AI. The company booked $176 million in 2025 revenue, growing at 40 percent year-over-year, which is serious commercial traction for its specialized non-invasive fractional flow reserve computed tomography (FFRct) analysis. HeartFlow’s revenue success is tied directly to its regulatory wins, including an FDA De Novo Pathway clearance and a subsequent CMS National Coverage Determination (NCD) that got them paid. Over in the monitoring space, iRhythm Technologies is in a different league entirely, with full-year 2025 revenue of $747.1 million and a projection of $880 million to $890 million for 2026. iRhythm’s huge revenue base is built on established demand and clear reimbursement for its AI-driven remote monitoring. Its long-term ambulatory ECG monitor, the Zio XT patch, is used everywhere, making the company a clear market leader. The gap between the overall market estimate and the revenue of even top players like HeartFlow and iRhythm is telling. It shows that the big market number is mostly measuring the promise of cardiac AI across a ton of applications, not the realized scale that’s been evenly distributed. A lot of those 100+ companies are still in the early stages, grinding through clinical validation and regulatory reviews with major revenue still years away.

What the Market Figures Actually Measure

So what do those big market numbers really mean? They’re a proxy for potential and investor interest, not a direct reflection of how commercially mature the whole sector is today. They capture:

• Technological Breadth: The fact that they include imaging, monitoring, and risk prediction shows just how many different ways AI can be applied in cardiology.
• Innovation Velocity: That 28.6 percent growth rate reflects a ton of investment in R&D and the fact that more clinicians are starting to use these tools.
• Investor Confidence: The huge amount of capital raised by companies like HeartFlow, long before they hit hundreds of millions in revenue, shows that investors have a strong belief in the long-term payday from cardiac AI.
• Emerging Opportunities: The sheer number of active companies means new niches are constantly being explored, and each one adds a little bit to that total market valuation.

But these numbers don’t separate the companies with a proven commercial engine from those still trying to get on the field. For investors, that’s the whole ballgame. A huge market estimate is nice to see, but a company’s ability to grab a real piece of it depends on a lot more than just clever tech.

The Gates to Revenue: FDA 510(k) and CMS National Coverage Determinations

Turning that market potential into sustainable revenue means getting through two main gates: the FDA 510(k) pathway and CMS National Coverage Determinations (NCDs). The FDA 510(k) pathway is how most medical devices, including many cardiac AI tools, get cleared for sale in the US. The process requires a company to prove its new device is “substantially equivalent” to an existing, legally marketed one. Even though it’s faster than the De Novo pathway, getting a 510(k) clearance still requires rigorous clinical data and strict adherence to quality management systems (QMS) FDA guidance on 510(k) submissions. For a cardiac AI algorithm, this usually means proving its performance is as good as or better than the current clinical standard. The FDA had cleared 154 cardiovascular AI devices as of June 2026, and since 96% of them used the 510(k) pathway, its importance is obvious. After getting FDA clearance, the next big hurdle is getting paid. CMS National Coverage Determinations (NCDs) are key for reimbursement, especially since they cover the huge Medicare population. An NCD sets the national rules for whether Medicare will pay for a technology and under what circumstances. HeartFlow’s story is the perfect example here. After its FFRct analysis got FDA clearance, it secured a critical NCD that opened the floodgates for commercial use and revenue growth. Without an NCD or another solid reimbursement plan (like dedicated CPT codes), even an FDA-cleared AI product can’t get wide adoption or generate real money. These regulatory and reimbursement hurdles are serious barriers to entry and scaling up. They explain why the revenue is so concentrated with a few winners, even while the overall market estimate keeps getting bigger. The companies that successfully get through these gates, proving both clinical and economic value, are the ones that turn the promise of AI into actual financial returns.

Conclusion

The cardiac AI market is set to grow at 28.6 percent a year, representing a massive field of new technology. But looking at specific company revenues, like HeartFlow’s $176 million in 2025 and iRhythm Technologies’ projected $880 million to $890 million for 2026, makes it clear that the headline number is a measure of the sector’s potential, not its current, evenly distributed scale. Turning that potential into real revenue depends entirely on working through the FDA’s strict requirements, mostly through the 510(k) pathway, and then securing reimbursement through mechanisms like CMS National Coverage Determinations. For anyone investing in or analyzing this space, the most important job is to distinguish between the broad market hype and the demonstrated commercial traction of an individual company, which is almost always a direct result of clearing those critical gates.